IBDEI0FF ; ; 13-FEB-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 13, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,20693,1,8,0)
 ;;=8^Oth Spec Hemorrhagic Conditions
 ;;^UTILITY(U,$J,358.3,20693,2)
 ;;=^88074
 ;;^UTILITY(U,$J,358.3,20694,0)
 ;;=287.9^^132^1234^27
 ;;^UTILITY(U,$J,358.3,20694,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20694,1,1,0)
 ;;=1^287.9
 ;;^UTILITY(U,$J,358.3,20694,1,8,0)
 ;;=8^Unspec Hemorrhagic Conditions
 ;;^UTILITY(U,$J,358.3,20694,2)
 ;;=^123920
 ;;^UTILITY(U,$J,358.3,20695,0)
 ;;=238.72^^132^1234^14
 ;;^UTILITY(U,$J,358.3,20695,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20695,1,1,0)
 ;;=1^238.72
 ;;^UTILITY(U,$J,358.3,20695,1,8,0)
 ;;=8^Low Grde Myelodysplastic Synd Lesions
 ;;^UTILITY(U,$J,358.3,20695,2)
 ;;=^334028
 ;;^UTILITY(U,$J,358.3,20696,0)
 ;;=238.73^^132^1234^12
 ;;^UTILITY(U,$J,358.3,20696,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20696,1,1,0)
 ;;=1^238.73
 ;;^UTILITY(U,$J,358.3,20696,1,8,0)
 ;;=8^Hi Grde Myelodysplastic Synd Lesions
 ;;^UTILITY(U,$J,358.3,20696,2)
 ;;=^334029
 ;;^UTILITY(U,$J,358.3,20697,0)
 ;;=238.75^^132^1234^15
 ;;^UTILITY(U,$J,358.3,20697,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20697,1,1,0)
 ;;=1^238.75
 ;;^UTILITY(U,$J,358.3,20697,1,8,0)
 ;;=8^Myelodysplastic Syndrome,Unspec
 ;;^UTILITY(U,$J,358.3,20697,2)
 ;;=^334031
 ;;^UTILITY(U,$J,358.3,20698,0)
 ;;=205.00^^132^1235^32
 ;;^UTILITY(U,$J,358.3,20698,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20698,1,1,0)
 ;;=1^205.00
 ;;^UTILITY(U,$J,358.3,20698,1,8,0)
 ;;=8^Myeloid Leukemia w/o Remission
 ;;^UTILITY(U,$J,358.3,20698,2)
 ;;=^267531
 ;;^UTILITY(U,$J,358.3,20699,0)
 ;;=205.01^^132^1235^31
 ;;^UTILITY(U,$J,358.3,20699,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20699,1,1,0)
 ;;=1^205.01
 ;;^UTILITY(U,$J,358.3,20699,1,8,0)
 ;;=8^Myeloid Leukemia in Remission
 ;;^UTILITY(U,$J,358.3,20699,2)
 ;;=^267532
 ;;^UTILITY(U,$J,358.3,20700,0)
 ;;=205.10^^132^1235^18
 ;;^UTILITY(U,$J,358.3,20700,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20700,1,1,0)
 ;;=1^205.10
 ;;^UTILITY(U,$J,358.3,20700,1,8,0)
 ;;=8^Chr Myeloid Leukemia w/o Remission
 ;;^UTILITY(U,$J,358.3,20700,2)
 ;;=^267533
 ;;^UTILITY(U,$J,358.3,20701,0)
 ;;=205.11^^132^1235^17
 ;;^UTILITY(U,$J,358.3,20701,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20701,1,1,0)
 ;;=1^205.11
 ;;^UTILITY(U,$J,358.3,20701,1,8,0)
 ;;=8^Chr Myeloid Leukemia in Remission
 ;;^UTILITY(U,$J,358.3,20701,2)
 ;;=^267534
 ;;^UTILITY(U,$J,358.3,20702,0)
 ;;=289.0^^132^1235^50
 ;;^UTILITY(U,$J,358.3,20702,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20702,1,1,0)
 ;;=1^289.0
 ;;^UTILITY(U,$J,358.3,20702,1,8,0)
 ;;=8^Secondary Polycythemia
 ;;^UTILITY(U,$J,358.3,20702,2)
 ;;=^186856
 ;;^UTILITY(U,$J,358.3,20703,0)
 ;;=238.4^^132^1235^48
 ;;^UTILITY(U,$J,358.3,20703,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20703,1,1,0)
 ;;=1^238.4
 ;;^UTILITY(U,$J,358.3,20703,1,8,0)
 ;;=8^Polycythemia Rubra Vera
 ;;^UTILITY(U,$J,358.3,20703,2)
 ;;=^96105
 ;;^UTILITY(U,$J,358.3,20704,0)
 ;;=288.9^^132^1235^67
 ;;^UTILITY(U,$J,358.3,20704,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20704,1,1,0)
 ;;=1^288.9
 ;;^UTILITY(U,$J,358.3,20704,1,8,0)
 ;;=8^Unspecified Dis Of W B C
 ;;^UTILITY(U,$J,358.3,20704,2)
 ;;=^267993
 ;;^UTILITY(U,$J,358.3,20705,0)
 ;;=289.81^^132^1235^49
 ;;^UTILITY(U,$J,358.3,20705,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20705,1,1,0)
 ;;=1^289.81
 ;;^UTILITY(U,$J,358.3,20705,1,8,0)
 ;;=8^Primary Hypercoagulable State
 ;;^UTILITY(U,$J,358.3,20705,2)
 ;;=^329886
 ;;^UTILITY(U,$J,358.3,20706,0)
 ;;=238.75^^132^1235^29
 ;;^UTILITY(U,$J,358.3,20706,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20706,1,1,0)
 ;;=1^238.75
 ;;^UTILITY(U,$J,358.3,20706,1,8,0)
 ;;=8^Myelodysplastic Syndrome
 ;;^UTILITY(U,$J,358.3,20706,2)
 ;;=^334031
 ;;^UTILITY(U,$J,358.3,20707,0)
 ;;=289.9^^132^1235^66
 ;;^UTILITY(U,$J,358.3,20707,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20707,1,1,0)
 ;;=1^289.9
 ;;^UTILITY(U,$J,358.3,20707,1,8,0)
 ;;=8^Unspecified Blood Disease
 ;;^UTILITY(U,$J,358.3,20707,2)
 ;;=^55344
 ;;^UTILITY(U,$J,358.3,20708,0)
 ;;=205.02^^132^1235^30
 ;;^UTILITY(U,$J,358.3,20708,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20708,1,1,0)
 ;;=1^205.02
 ;;^UTILITY(U,$J,358.3,20708,1,8,0)
 ;;=8^Myeloid Leukemia in Relapse
 ;;^UTILITY(U,$J,358.3,20708,2)
 ;;=^336470
 ;;^UTILITY(U,$J,358.3,20709,0)
 ;;=205.12^^132^1235^16
 ;;^UTILITY(U,$J,358.3,20709,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20709,1,1,0)
 ;;=1^205.12
 ;;^UTILITY(U,$J,358.3,20709,1,8,0)
 ;;=8^Chr Myeloid Leukemia in Relapse
 ;;^UTILITY(U,$J,358.3,20709,2)
 ;;=^336471
 ;;^UTILITY(U,$J,358.3,20710,0)
 ;;=205.20^^132^1235^59
 ;;^UTILITY(U,$J,358.3,20710,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20710,1,1,0)
 ;;=1^205.20
 ;;^UTILITY(U,$J,358.3,20710,1,8,0)
 ;;=8^Subacute Myeloid Leuk w/o Remiss
 ;;^UTILITY(U,$J,358.3,20710,2)
 ;;=^336857
 ;;^UTILITY(U,$J,358.3,20711,0)
 ;;=205.21^^132^1235^58
 ;;^UTILITY(U,$J,358.3,20711,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20711,1,1,0)
 ;;=1^205.21
 ;;^UTILITY(U,$J,358.3,20711,1,8,0)
 ;;=8^Subacute Myeloid Leuk in Remiss
 ;;^UTILITY(U,$J,358.3,20711,2)
 ;;=^267536
 ;;^UTILITY(U,$J,358.3,20712,0)
 ;;=205.22^^132^1235^57
 ;;^UTILITY(U,$J,358.3,20712,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20712,1,1,0)
 ;;=1^205.22
 ;;^UTILITY(U,$J,358.3,20712,1,8,0)
 ;;=8^Subacute Myeloid Leuk in Relapse
 ;;^UTILITY(U,$J,358.3,20712,2)
 ;;=^336472
 ;;^UTILITY(U,$J,358.3,20713,0)
 ;;=205.30^^132^1235^35
 ;;^UTILITY(U,$J,358.3,20713,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20713,1,1,0)
 ;;=1^205.30
 ;;^UTILITY(U,$J,358.3,20713,1,8,0)
 ;;=8^Myeloid Sarcoma w/o Remission
 ;;^UTILITY(U,$J,358.3,20713,2)
 ;;=^336858
 ;;^UTILITY(U,$J,358.3,20714,0)
 ;;=205.31^^132^1235^34
 ;;^UTILITY(U,$J,358.3,20714,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20714,1,1,0)
 ;;=1^205.31
 ;;^UTILITY(U,$J,358.3,20714,1,8,0)
 ;;=8^Myeloid Sarcoma in Remission
 ;;^UTILITY(U,$J,358.3,20714,2)
 ;;=^267538
 ;;^UTILITY(U,$J,358.3,20715,0)
 ;;=205.32^^132^1235^33
 ;;^UTILITY(U,$J,358.3,20715,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20715,1,1,0)
 ;;=1^205.32
 ;;^UTILITY(U,$J,358.3,20715,1,8,0)
 ;;=8^Myeloid Sarcoma in Relapse
 ;;^UTILITY(U,$J,358.3,20715,2)
 ;;=^336473
 ;;^UTILITY(U,$J,358.3,20716,0)
 ;;=205.80^^132^1235^44
 ;;^UTILITY(U,$J,358.3,20716,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20716,1,1,0)
 ;;=1^205.80
 ;;^UTILITY(U,$J,358.3,20716,1,8,0)
 ;;=8^Oth Myeloid Leukemia w/o Remission
 ;;^UTILITY(U,$J,358.3,20716,2)
 ;;=^336859
 ;;^UTILITY(U,$J,358.3,20717,0)
 ;;=205.81^^132^1235^43
 ;;^UTILITY(U,$J,358.3,20717,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20717,1,1,0)
 ;;=1^205.81
 ;;^UTILITY(U,$J,358.3,20717,1,8,0)
 ;;=8^Oth Myeloid Leukemia in Remission
 ;;^UTILITY(U,$J,358.3,20717,2)
 ;;=^267540
 ;;^UTILITY(U,$J,358.3,20718,0)
 ;;=205.82^^132^1235^42
 ;;^UTILITY(U,$J,358.3,20718,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20718,1,1,0)
 ;;=1^205.82
 ;;^UTILITY(U,$J,358.3,20718,1,8,0)
 ;;=8^Oth Myeloid Leukemia in Relapse
 ;;^UTILITY(U,$J,358.3,20718,2)
 ;;=^336474
 ;;^UTILITY(U,$J,358.3,20719,0)
 ;;=205.90^^132^1235^65
 ;;^UTILITY(U,$J,358.3,20719,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20719,1,1,0)
 ;;=1^205.90
 ;;^UTILITY(U,$J,358.3,20719,1,8,0)
 ;;=8^Unspec Myeloid Leuk w/o Remission
 ;;^UTILITY(U,$J,358.3,20719,2)
 ;;=^336860
 ;;^UTILITY(U,$J,358.3,20720,0)
 ;;=205.91^^132^1235^64
 ;;^UTILITY(U,$J,358.3,20720,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20720,1,1,0)
 ;;=1^205.91
 ;;^UTILITY(U,$J,358.3,20720,1,8,0)
 ;;=8^Unspec Myeloid Leuk in Remission
 ;;^UTILITY(U,$J,358.3,20720,2)
 ;;=^267542
 ;;^UTILITY(U,$J,358.3,20721,0)
 ;;=205.92^^132^1235^63
 ;;^UTILITY(U,$J,358.3,20721,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20721,1,1,0)
 ;;=1^205.92
 ;;^UTILITY(U,$J,358.3,20721,1,8,0)
 ;;=8^Unspec Myeloid Leuk in Relapse
 ;;^UTILITY(U,$J,358.3,20721,2)
 ;;=^336475
 ;;^UTILITY(U,$J,358.3,20722,0)
 ;;=206.00^^132^1235^6
 ;;^UTILITY(U,$J,358.3,20722,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20722,1,1,0)
 ;;=1^206.00
 ;;^UTILITY(U,$J,358.3,20722,1,8,0)
 ;;=8^Acute Monocytic Leuk w/o Remission
 ;;^UTILITY(U,$J,358.3,20722,2)
 ;;=^336861
 ;;^UTILITY(U,$J,358.3,20723,0)
 ;;=206.01^^132^1235^5
 ;;^UTILITY(U,$J,358.3,20723,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20723,1,1,0)
 ;;=1^206.01
 ;;^UTILITY(U,$J,358.3,20723,1,8,0)
 ;;=8^Acute Monocytic Leuk in Remission
 ;;^UTILITY(U,$J,358.3,20723,2)
 ;;=^267544
 ;;^UTILITY(U,$J,358.3,20724,0)
 ;;=206.02^^132^1235^4
 ;;^UTILITY(U,$J,358.3,20724,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20724,1,1,0)
 ;;=1^206.02
 ;;^UTILITY(U,$J,358.3,20724,1,8,0)
 ;;=8^Acute Monocytic Leuk in Relapse
 ;;^UTILITY(U,$J,358.3,20724,2)
 ;;=^336476
 ;;^UTILITY(U,$J,358.3,20725,0)
 ;;=206.10^^132^1235^15
 ;;^UTILITY(U,$J,358.3,20725,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20725,1,1,0)
 ;;=1^206.10
 ;;^UTILITY(U,$J,358.3,20725,1,8,0)
 ;;=8^Chr Monocytic Leuk w/o Remission
 ;;^UTILITY(U,$J,358.3,20725,2)
 ;;=^336862
 ;;^UTILITY(U,$J,358.3,20726,0)
 ;;=206.11^^132^1235^14
 ;;^UTILITY(U,$J,358.3,20726,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20726,1,1,0)
 ;;=1^206.11
 ;;^UTILITY(U,$J,358.3,20726,1,8,0)
 ;;=8^Chr Monocytic Leuk in Remission
 ;;^UTILITY(U,$J,358.3,20726,2)
 ;;=^267546
 ;;^UTILITY(U,$J,358.3,20727,0)
 ;;=206.12^^132^1235^13
 ;;^UTILITY(U,$J,358.3,20727,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20727,1,1,0)
 ;;=1^206.12
 ;;^UTILITY(U,$J,358.3,20727,1,8,0)
 ;;=8^Chr Monocytic Leuk in Relapse
 ;;^UTILITY(U,$J,358.3,20727,2)
 ;;=^336477
 ;;^UTILITY(U,$J,358.3,20728,0)
 ;;=206.20^^132^1235^55
 ;;^UTILITY(U,$J,358.3,20728,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20728,1,1,0)
 ;;=1^206.20
 ;;^UTILITY(U,$J,358.3,20728,1,8,0)
 ;;=8^Subacute Monocytic Leuk w/o Remiss
 ;;^UTILITY(U,$J,358.3,20728,2)
 ;;=^336863
 ;;^UTILITY(U,$J,358.3,20729,0)
 ;;=206.21^^132^1235^54
 ;;^UTILITY(U,$J,358.3,20729,1,0)
 ;;=^358.31IA^8^2
